Imulan BioTherapeutics Licenses New Immune Modulator
19 years ago
5903 views
Posted
7th January, 2007 00h00
SCOTTSDALE, Ariz. – (January 7th, 2007) Imulan BioTherapeutics, LLC (Imulan), a privately-held bioscience company, announced the worldwide licensing of a novel immune modulating vaccine technology for animal health applications.
Dr. Craig Woods, CEO of Imulan, stated, “The vaccine proposes to manage a number of conditions, including allergic reactions, infections, cancer and autoimmune disorders. Studies indicate the vaccine helps to restore normal T-helper cell activity and cytokine balance. The potential applications in livestock and companion animals may provide veterinarians a much needed tool to manage a significant number of clinically challenging conditions.“
Founded in 2004, Imulan has initiated the development of several platform technologies, including the ImSAIDs™, for animal health. Imulan is focused on developing unique immune regulating compounds with predictable effects. For more information about Imulan, please visit
www.imulan.com.
More from
